Trial · NCT07903753
RISE for PTSD and Substance Use Disorder in Veterans
NCT07903753, Not applicable, Not yet recruiting, VA Office of Research and Development
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RISE for PTSD and Substance Use Disorder in Veterans. Trials, record NCT07903753. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903753
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RISE for PTSD and Substance Use Disorder in Veterans
- NCT number
- NCT07903753
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Stress Disorders, Post-Traumatic, Substance-Related Disorders
- Interventions
- Written Exposure Therapy, Cognitive Behavioral Therapy for Substance Use Disorders (skill components), Cognitive Behavioral Therapy for Substance Use Disorders
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility: Participant Recruitment | Baseline | Rate of eligible screened Veterans and enrollment rate, used as an indicator of the reach and accessibility of RISE. |
| Primary | Feasibility: Study Retention | post-treatment (6 weeks), 3-month follow-up | Proportion of enrolled participants retained through study completion. |
| Primary | Feasibility: Number of Sessions Attended | 6 weeks | Average number of treatment sessions attended by participants in each arm, used as a behavioral indicator of treatment engagement. |
| Primary | Feasibility: Treatment Completion | 6 weeks | Proportion of participants who complete all six treatment sessions, used as a behavioral indicator of feasibility. |
| Primary | Feasibility: Study Withdrawals | post-treatment (6 weeks), 3-month follow-up | Number and proportion of participants who withdraw from the study prior to treatment completion. |
| Primary | Acceptability: Client Satisfaction Questionnaire-8 (CSQ-8) Score | 6 weeks | The CSQ-8 is an 8-item measure of participant satisfaction with treatment. A mean score of 24 or higher corresponds to sufficient overall treatment satisfaction. |
| Secondary | Treatment Acceptability and Adherence Scale (TAAS) | Baseline | A self-report measure of participants' expectations regarding the acceptability and credibility of their assigned treatment. |
| Secondary | Revised Vanderbilt Therapeutic Alliance Scale, Short Form (VTAS-R) | 6 weeks | A brief self-report measure of the quality of the therapeutic relationship between participant and therapist. |
| Secondary | Demographic Questionnaire | Baseline | Standard sociodemographic data including age, sex, race, ethnicity, and education. |
| Secondary | Treatment History Form | Baseline, post-treatment (6 weeks), 3-month follow-up | Self-report measure assessing prior and concurrent utilization of mental health and substance use treatment services. |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903753
GET https://conductscience.org/api/trials/v1/NCT07903753/registered?page=2